4
Changes in Ownership
GeneDx Holdings Corp. Filed Acc 0001689575-26-000026
CHIEF EXECUTIVE OFFICER sold 3,639 shares at $53.77 ($195,669)
- CHIEF EXECUTIVE OFFICER acquired 6,546 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-06-09 | Option exercise | +6,546 | 99,762 | D: show line 1 in the form | ||
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-06-09 | Sale | −3,639 | $53.77 | $195,669 | 96,123 | D: show line 2 in the form |
| Open-market sales · 3,639 sh · avg $53.77 · $195,669 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-06-09 | Option exercise · Restricted Stock Unit | −6,546 | 13,094 | D: show line 3 in the form |
Loading xslF345X06/form4-06112026_080609.xml…